| Abstrakt: |
Sotalol (Sotacor) is a beta-adrenergic receptor blocking agent, which in addition possesses class III anti-arrhythmic properties. In this study we report on the clinical effectiveness of sotalol in the suppression of ventricular ectopic beats in 20 patients suffering from ischaemic heart disease. Sotalol was compared with placebo and efficacy was determined by Holter tape monitoring. Sotalol produced an 88,5% (P < 0,001) reduction in ectopic beat frequency at the optimal titrated dosage, with relatively few physical or biochemical side-effects. In situations where ventricular anti-arrhythmic therapy is deemed necessary, especially if long-term use is considered, sotalol seems to be the agent of choice. |
